The features of mucosa-associated microbiota in primary sclerosing cholangitis

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 7, 2016, Pages 790-801

  Torres, J ^a   Bao, X ^a   Goel, A ^a   Colombel, J F ^a   Pekow, J ^b   Jabri, B ^b   Williams, K M ^b   Castillo, A ^a   Odin, J A ^a   Meckel, K ^b   Fasihuddin, F ^a   Peter, I ^a   Itzkowitz, S ^a   Hu, J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA 16S;

ADULT; ALCALIGENACEAE; ARTICLE; BACTERIUM; BACTEROIDALES; BARNESIELLACEAE; BLAUTIA; CLINICAL ARTICLE; CLOSTRIDIALES; COLON; COLONOSCOPY; COMPARATIVE STUDY; CONTROLLED STUDY; FAMILIA; FEMALE; GENUS; HUMAN; HUMAN TISSUE; INFLAMMATORY BOWEL DISEASE; INTESTINE BIOPSY; INTESTINE FLORA; MALE; NONHUMAN; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RNA SEQUENCE; TERMINAL ILEUM; AGED; CHOLANGITIS, SCLEROSING; CLINICAL TRIAL; COLITIS, ULCERATIVE; GENETICS; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES;

ADULT; AGED; CHOLANGITIS, SCLEROSING; COLITIS, ULCERATIVE; COLONOSCOPY; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MICROBIOTA; MIDDLE AGED; RNA, RIBOSOMAL, 16S;

EID: 84959450854     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13552     Document Type: Article

References (49)

1. Fausa O, Schrumpf E, Elgjo K,. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 31-9.
2. Rasmussen HH, Fallingborg JF, Mortensen PB, Vyberg M, Tage-Jensen U, Rasmussen SN,. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997; 32: 604-10.
3. Olsson R, Danielsson A, Jarnerot G, et al,. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-23.
4. Rahman M, Desmond P, Mortensen N, Chapman R,. The clinical impact of primary sclerosing cholangitis in patients with an ileal pouch-anal anastomosis for ulcerative colitis. Int J Colorectal Dis 2011; 26: 553-9.
5. Loftus EV Jr, Harewood GC, Loftus CG, et al,. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-6.
6. Lundqvist K, Broome U,. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997; 40: 451-6.
7. Sokol H, Cosnes J, Chazouilleres O, et al,. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 2008; 14: 3497-503.
8. Navaneethan U, Choudhary M, Venkatesh PG, et al,. The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2012; 35: 1054-63.
9. Torres J, de Pineton Chambrun G, Itzkowitz S, Sachar DB, Colombel JF,. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 497-508.
10. Eaton JE, Smyrk TC, Imam M, et al,. The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation. Aliment Pharmacol Ther 2013; 38: 977-87.
11. Eaton JE, Juran BD, Atkinson EJ, et al,. A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther 2015; 41: 980-90.
12. Tabibian JH, O'Hara SP, Lindor KD,. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol 2014; 49: 901-8.
13. Tabibian JH, Talwalkar JA, Lindor KD,. Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int 2013; 2013: 389537.
14. Tabibian JH, Weeding E, Jorgensen RA, et al,. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis-a pilot study. Aliment Pharmacol Ther 2013; 37: 604-12.
15. Paterson JC, Dillon JF,. Commentary: vancomycin or metronidazole in patients with primary sclerosing cholangitis? Aliment Pharmacol Ther 2013; 37: 915.
16. Davies YK, Tsay CJ, Caccamo DV, Cox KM, Castillo RO, Cox KL,. Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin. Case Rep Transplant 2013; 2013: 314292.
17. Schnabl B, Brenner DA,. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146: 1513-24.
18. Rossen NG, Fuentes S, Boonstra K, et al,. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis 2015; 9: 342-8.
19. Sinakos E, Marschall H-U, Kowdley KV, Befeler A, Keach J, Lindor K,. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression. Hepatology 2010; 52: 197-203.
20. Kakiyama G, Pandak WM, Gillevet PM, et al,. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013; 58: 949-55.
21. Bajaj JS, Ridlon JM, Hylemon PB, et al,. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012; 302: G168-75.
22. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS,. Bile acids and the gut microbiome. Curr Opin Gastroenterol 2014; 30: 332-8.
23. Ridlon JM, Kang DJ, Hylemon PB,. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47: 241-59.
24. Lennard-Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6; discussion 16-9.
25. Ahn J, Yang L, Paster BJ, et al,. Oral microbiome profiles: 16S rRNA pyrosequencing and microarray assay comparison. PLoS ONE 2011; 6: e22788.
26. Hu J, Franzen O, Pei Z, Itzkowitz S, Peter I,. P-237 multiple double-barcoding 16S sequencing on the MiSeq platform to study the gut microbiome in Ashkenazi Jews with Crohn's disease. Inflamm Bowel Dis 2013; 19: S119-21.
27. Tong M, McHardy I, Ruegger P, et al,. Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 2014; 8: 2193-206.
28. Price LB, Liu CM, Johnson KE, et al,. The effects of circumcision on the penis microbiome. PLoS ONE 2010; 5: e8422.
29. Chen J, Bittinger K, Charlson ES, et al,. Associating microbiome composition with environmental covariates using generalized UniFrac distances. Bioinformatics 2012; 28: 2106-13.
30. Oksanen J,. Multivariate analysis of ecological communities in R: vegan tutorial, 2013.
31. Aagaard K, Riehle K, Ma J, et al,. A metagenomic approach to characterization of the vaginal microbiome signature in pregnancy. PLoS ONE 2012; 7: e36466.
32. Sze MA, Tsuruta M, Yang SW, et al,. Changes in the bacterial microbiota in gut, blood, and lungs following acute LPS instillation into mice lungs. PLoS ONE 2014; 9: e111228.
33. Morgan XC, Huttenhower C,. Chapter 12: human microbiome analysis. PLoS Comput Biol 2012; 8): e1002808. doi 10.1371/Journal.Pcbi.1002808
34. Shannon CE,. A mathematical theory of communication. At&T Tech J 1948; 27: 623-56.
35. Caporaso JG, Kuczynski J, Stombaugh J, et al,. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010; 7: 335-6.
36. Morgan XC, Tickle TL, Sokol H, et al,. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13: R79.
37. Stearns JC, Lynch MD, Senadheera DB, et al,. Bacterial biogeography of the human digestive tract. Sci Rep 2011; 1: 170.
38. Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM,. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 2002; 68: 3401-7.
39. Torres J, Bao X, Iuga AC, et al,. Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. Inflamm Bowel Dis 2013; 19: 275-82.
40. Karlsson F, Tremaroli V, Nielsen J, Backhed F,. Assessing the human gut microbiota in metabolic diseases. Diabetes 2013; 62: 3341-9.
41. Kevans D, Tyler AD, Holm K, et al,. Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis. J Crohns Colitis 2015; pii: jjv204.
42. Bornigen D, Morgan XC, Franzosa EA, et al,. Functional profiling of the gut microbiome in disease-associated inflammation. Genome Med 2013; 5: 65.
43. Gevers D, Kugathasan S, Denson Lee A, et al,. The treatment-naive microbiome in new-onset Crohn's Disease. Cell Host Microbe 2014; 15: 382-92.
44. Rajilic-Stojanovic M, de Vos WM,. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev 2014; 38: 996-1047.
45. Narushima S, Itoha K, Miyamoto Y, et al,. Deoxycholic acid formation in gnotobiotic mice associated with human intestinal bacteria. Lipids 2006; 41: 835-43.
46. Atarashi K, Tanoue T, Oshima K, et al,. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013; 500: 232-6.
47. Islam KB, Fukiya S, Hagio M, et al,. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011; 141: 1773-81.
48. Hruz P, Zimmermann C, Gutmann H, et al,. Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. Gut 2006; 55: 395-402.
49. Sauer P, Stiehl A, Fitscher BA,. Downregulation of ileal bile acid absorption in bile-duct-ligated rats. J Hepatol 2000; 33: 2-8.